• Civetta Therapeutics Unveils a Propeller Protein Plan, $53M in Funding

    8 days ago - By Xconomy

    New biotech company Civetta Therapeutics has closed a $53 million Series A financing round to develop drugs that target “propeller proteins” as a way of treating cancers and other diseases. Propeller proteins are found throughout nature, and the circularly arranged “blades” of these proteins commonly serve as active sites to which molecules can bind. Bruce Goldsmith, a venture partner at Deerfield Management and Civetta's interim CEO, says propeller domains, the structural scaffolds of these proteins, have not been “fully exploited” for therapeutic drug discovery. “Propeller domains have...
    Read more ...